VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: GPSite who wrote (19)	6/7/1999 1:54:00 PM
From: William Stanton	Read Replies (4) of 250

I'm not afraid to guess on the IPO price. I took an informal survey of average people, all of whom had annual incomes under 50K -- I told them briefly about the company and the product, the risks and potential rewards. There were no people who would not pay $50 per share for the stock. 30% would pay up to $90 per share; 52% would pay up to $75. I think that GPSite's point concerning the prices of Entremed and Centocor are well taken. The public will pay, big-time for this IPO. It will be a BREAKTHROUGH IPO for Biotechs. The IPO goes to 50, day one -- to 100 within a month.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next